Transfusion haemosiderosis and chelation therapy.
D000293:Adolescent; D000328:Adult; D001205:Ascorbic Acid / Q000627:therapeutic use; D001803:Blood Transfusion; D009202:Cardiomyopathies / Q000378:metabolism / Q000473:pathology; D003676:Deferoxamine / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005293:Ferritins / Q000097:blood; D006130:Growth Disorders / Q000378:metabolism; D006331:Heart Diseases / Q000503:physiopathology; D006486:Hemosiderosis / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D007501:Iron / Q000633:toxicity; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D008099:Liver / Q000378:metabolism; D008107:Liver Diseases / Q000378:metabolism; D010182:Pancreatic Diseases / Q000378:metabolism; D010279:Parathyroid Diseases / Q000378:metabolism; D010900:Pituitary Diseases / Q000378:metabolism; D013960:Thyroid Function Tests
D007502:Iron Chelating Agents; D005293:Ferritins; D007501:Iron; D003676:Deferoxamine; D001205:Ascorbic Acid